Success and failure of dead-time models as applied to hybrid pixel detectors in high-flux applications.

The performance of a single-photon-counting hybrid pixel detector has been investigated at the Australian Synchrotron. Results are compared with the body of accepted analytical models previously validated with other detectors. Detector functionals are valuable for empirical calibration. It is shown that the matching of the detector dead-time with the temporal synchrotron source structure leads to substantial improvements in count rate and linearity of response. Standard implementations are linear up to ∼0.36 MHz pixel(-1); the optimized linearity in this configuration has an extended range up to ∼0.71 MHz pixel(-1); these are further correctable with a transfer function to ∼1.77 MHz pixel(-1). This new approach has wide application both in high-accuracy fundamental experiments and in standard crystallographic X-ray fluorescence and other X-ray measurements. The explicit use of data variance (rather than N(1/2) noise) and direct measures of goodness-of-fit (χ(r)(2)) are introduced, raising issues not encountered in previous literature for any detector, and suggesting that these inadequacies of models may apply to most detector types. Specifically, parametrization of models with non-physical values can lead to remarkable agreement for a range of count-rate, pulse-frequency and temporal structure. However, especially when the dead-time is near resonant with the temporal structure, limitations of these classical models become apparent. Further, a lack of agreement at extreme count rates was evident.

Observation of picometer vertical emittance with a vertical undulator.

Using a vertical undulator, picometer vertical electron beam emittances have been observed at the Australian Synchrotron storage ring. An APPLE-II type undulator was phased to produce a horizontal magnetic field, which creates a synchrotron radiation field that is very sensitive to the vertical electron beam emittance. The measured ratios of undulator spectral peak heights are evaluated by fitting to simulations of the apparatus. With this apparatus immediately available at most existing electron and positron storage rings, we find this to be an appropriate and novel vertical emittance diagnostic.

Higgs physics at the CLIC electron-positron linear collider.

The Compact Linear Collider (CLIC) is an option for a future [Formula: see text] collider operating at centre-of-mass energies up to [Formula: see text], providing sensitivity to a wide range of new physics phenomena and precision physics measurements at the energy frontier. This paper is the first comprehensive presentation of the Higgs physics reach of CLIC operating at three energy stages: [Formula: see text], 1.4 and [Formula: see text]. The initial stage of operation allows the study of Higgs boson production in Higgsstrahlung ([Formula: see text]) and [Formula: see text]-fusion ([Formula: see text]), resulting in precise measurements of the production cross sections, the Higgs total decay width [Formula: see text], and model-independent determinations of the Higgs couplings. Operation at [Formula: see text] provides high-statistics samples of Higgs bosons produced through [Formula: see text]-fusion, enabling tight constraints on the Higgs boson couplings. Studies of the rarer processes [Formula: see text] and [Formula: see text] allow measurements of the top Yukawa coupling and the Higgs boson self-coupling. This paper presents detailed studies of the precision achievable with Higgs measurements at CLIC and describes the interpretation of these measurements in a global fit.

Glutamate synthase (NADH) from lupin nodules. Specificity of the 2-oxoglutarate site.

The binding of substrate analogues including potential alternative substrates, to glutamate synthase (NADH) (L-glutamate: NAD+ oxidoreductase (transaminating) E.C. 1.4.1.14) has been investigated by studying competitive inhibition with respect ot 2-oxoglutarate. Binding requires two terminal carboxyl groups on a C5 straight chain molecule although some C4 molecules bind weakly. Bulky substituents at C2 decrease or prevent binding. Glutarate, the most potent inhibitor, binds much less tightly than the substrate. A 2-oxo group in a molecule other than the substrate does not appear to contribute significantly to binding. None of the analogues was able to act as an alternative substrate.

The specificity of actinidin and its relationship to the structure of the enzyme.

The kinetic parameters kcat, Km and kcat/Km, have been determined for the actinidin-catalysed hydrolyses of N-substituted amino acid esters and amides and compared to the corresponding values for papain (EC 3.4.22.2). Substrates with aromatic N-substituents have lower kcat/Km values for actinidin (EC 3.4.22.14); the difference is much smaller for substrates with aliphatic substituents. The lower kcat/Km values for actinidin generally correspond to higher Km values suggesting that the strength of substrate binding differs between the two enzymes. This difference is explained in terms of the differences in the substrate binding sites found in X-ray crystallographic studies.

The 12-lead electrocardiogram in exercise testing. A misleading baseline?

Mason and Likar reported a modified ECG lead system that largely eliminates intraexercise artifact without reportedly altering the configuration of the recorded leads. This system allows continuous monitoring of all 12 leads during and after exercise and has become the standard by which other systems are compared. We have found, however, that important changes may be seen between the baseline exercise ECG using the Mason-Likar modification and a simultaneous standard ECG. While these differences do not apparently affect the interpretation of the test, they may produce or obscure evidence of antecedent infarction on the baseline exercise ECG and thus preclude it from being considered interchangeable with a standard ECG.

A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure.

Benazepril hydrochloride is a nonsulfhydryl, long-acting angiotensin-converting enzyme inhibitor that is orally effective. This study was designed to determine the acute hemodynamic effects of this agent in patients with chronic congestive heart failure. Twenty-six patients with New York Heart Association class III or IV congestive heart failure and left ventricular ejection fractions less than 35%, cardiac indexes less than 2.1 L/min/m2, and pulmonary artery wedge pressures greater than 12 mm Hg were given 2 or 5 mg benazepril hydrochloride. All does produced significant (p less than 0.05) increases in cardiac output (26.7% to 31.6% above control) and heart rate (5.4% to 11.2% above control) and decreases in systemic (27.1% to 32.0% below control) and pulmonary (34.8% to 55.5% below control) vascular resistances, mean pulmonary (25.3% to 30.3% below control) and systemic (13.4% to 18.5% below control) arterial pressures, and pulmonary artery wedge pressure (46.9% to 51.1% below control). Twenty-four hours after an initial dose, systemic vascular resistance and pulmonary artery wedge pressures remained below control levels. Angiotensin-converting enzyme activity fell by 67.8% +/- 6.4%, with a 15.8% +/- 7.6% decline in aldosterone levels. Thus benazepril hydrochloride is an effective angiotensin-converting enzyme inhibitor that produces hemodynamic effects that persist for 24 hours after a single oral dose.

Extractive purification of enzymes from animal tissue using aqueous two phase systems: pilot scale studies.

Pilot scale trials have been carried out to assess the feasibility of using PEG-salt aqueous phase systems for extraction and purification of enzymes from animal tissue on an industrial scale. Comminuted bovine liver was used as a starting material, and it was easy to separate a clear upper phase containing proteins of interest from a mixture containing 20% biomass, 15% PEG and 8% phosphate using a disc separator. Similar attempts with decanters were unsuccessful. Second-phase separation was simply accomplished by the addition of salt to the separated, clear upper layer and standing or allowing passage through a disc separator. The method was tested using continuous mixing on the GBF continuous mixing aqueous phase extraction plant, with and without computer control. Good separations were achieved. The enzyme superoxide dismutase was purified using this method yielding a 4-fold purification factor with respect to soluble protein and a recovery rate of 83%, with the enzyme in a clarified solution suitable for further processing by chromatographic methods. The general applicability of this method, its economics and its potential application in industry are discussed.

Chronic therapy for congestive heart failure with benazepril HCl, a new angiotensin converting enzyme inhibitor.

Benazepril HCl is an orally effective angiotensin converting enzyme (ACE) inhibitor previously shown to have significant acute hemodynamic benefits in patients with congestive heart failure. In this study, 21 patients with New York Heart Association Class III or IV congestive heart failure were treated with 2 to 15 mg of benazepril HCl as a single daily oral dose for 28 days to determine the clinical and hemodynamic value of chronic therapy. Each patient underwent clinical evaluation during the 28-day period, as well as invasive hemodynamic studies on the first two and last two days of the trial. Plasma ACE activity and aldosterone levels fell significantly and renin levels rose after therapy. Benazepril HCl produced significant (p less than 0.01) reductions in arterial pressure and systemic vascular resistance, with corresponding increases in cardiac output and decreases in pulmonary artery wedge pressure. Responses after 28 days of therapy were equivalent to those after the initial doses. Clinical effects included reduced rest, exertional and paroxysmal nocturnal dyspnea, as well as reduced peripheral edema. Only one patient developed symptomatic orthostatic hypotension. Thus, benazepril HCl, given once daily, is an effective and well tolerated oral agent for the chronic treatment of advanced congestive heart failure.

Extraction and purification of proteins from animal tissue using aqueous phase systems.

Aqueous phase separations offer a novel and different means of extracting and purifying proteins from animal tissue at industrial scale. This article gives an overview of aqueous phase separations in relation to animal tissue, describes some pilot-scale work, and discusses the strengths, weaknesses and future prospects for this technology.

Extraction of proteins from animal tissue using multiphase aqueous systems.

Animal tissue is likely to continue to be an important source of enzymes and protein hormones well into the 21st century. Aqueous phase systems show considerable potential and specific advantages for extractive purification of proteins from animal tissue. Although no industrial process is yet in place for commercial production of a protein from animal tissue, the potential for the system has, however, been demonstrated at laboratory scale for a number of enzymes, and at pilot scale for a few, using simple phase systems and also affinity partitioning systems. Pertinent features of these systems are reviewed, and process and economic aspects discussed.

Kinetic mechanism of NADH-dependent glutamate synthase from lupin nodules.

From initial-rate studies, a partially random kinetic mechanism has been deduced for NADH-dependent glutamate synthase from lupin nodules. The mechanism involves compulsory binding of NADH as first substrate, followed by random-order binding of glutamine and 2-oxoglutarate. Patterns of inhibition by glutamate substantiate the mechanism. Dithionite was incapable of acting as an alternative reducing substrate although it is known to reduce the flavine groups of the enzyme. The implications of these results are discussed. Published rate equations for this type of mechanism were found to be unsatisfactory for this enzyme and suitable new equations are produced. These equations should have general application where the obligatory first substrate binds very tightly.

NADH-dependent glutamate synthase from lupin nodules. Reactions with oxidised and reduced 3-acetylpyridine-adenine dinucleotide.

3-Acetylpyridine-adenine dinucleotide, reduced form (AcPdADH) is able to act as an alternative reductant in glutamate-synthase-catalysed glutamate synthesis. In the AcPdADH-dependent reaction, kcat and Km values for the other substrates are fourfold lower than those for the NADH-dependent reaction, and Km for AcPdADH is about 3 microM. AcPdADH acts as a competitive inhibitor with respect to NADH in NADH-dependent glutamate synthesis, with a Ki of 1 microM. Glutamate synthase catalyses NADH-dependent reduction of AcPdAD+. This appears to proceed by a substituted-enzyme (ping-pong) mechanism, with competitive substrate inhibition by NADH at high levels. The Km values for this reaction are 1.4 microM for NADH and 14 microM for AcPdAD+ and kcat is 51 s-1; Ki for NADH is about 10 microM. The latter findings suggest that NADH is capable of reducing the enzyme molecule in the absence of other substrates and that a reduced form of the enzyme can exist in the absence of bound NADH.

Enzymes of nitrogen metabolism in legume nodules. Purification and properties of NADH-dependent glutamate synthase from lupin nodules.

An NADH-dependent glutamate synthase has been purified 500-fold from the plant cytoplasm fraction of Lupinus angustifolius nodules. It consists of a single polypeptide chain, Mr 235000. The optimum pH is 8.5, at which Km values for 2-oxoglutarate, glutamine and NADH are 39 micrometer, 400 micrometer and 1.3 micrometer respectively. The catalytic centre activity is of the order of 70 s-1 and is independent of pH between 6.5 and 9.5. Glutamate synthase is inhibited by glutamic acid, oxaloacetic acid, aspartic acid and asparagine, all competitive with 2-oxoglutarate; and by NAD+, which is competitive with NADH. There is evidence of two flavine prosthetic groups per enzyme molecule.